Paper
0
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Authors
Yi‐Long Wu,Valentina Guarneri
Pei Voon,Boon Lim,Jin‐Ji Yang,Marie Wislez,Cheng Huang,Chong Liam,Julien Mazieres,Lye Tho,Hidetoshi Hayashi,Nhung Nguyen,Puey Chia,Filippo Marinis,Jo Raskin,Qinghua Zhou,Giovanna Finocchiaro,Anh Le,Jialei Wang,Christophe Dooms,Terufumi Kato,Ernest Nadal,Soon How,Egbert Smit,Martin Wermke,Daniel Tan,Masahiro Morise,Aurora O’Brate,Svenja Adrian,Boris Pfeiffer,Christopher Stroh,Dilafruz Juraeva,Rainer Strotmann,Kosalaram Goteti,Karin Berghoff,Barbara Ellers‐Lenz,Niki Karachaliou,Xiuning Le
+36 authors
,Tae KimJournal
Published
Jul 29, 2024
Show more
Save
Tip0
TipSave
Abstract
Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of the phase 2 INSIGHT 2 study evaluating tepotinib, a highly selective MET inhibitor, combined with osimertinib in this population.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.